GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Price-to-Owner-Earnings

Paion Ag (Paion Ag) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Price-to-Owner-Earnings?

As of today (2024-05-17), Paion Ag's share price is $0.0251. Paion Ag does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Paion Ag's Price-to-Owner-Earnings or its related term are showing as below:

PAIOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.5   Med: 271.67   Max: 4160
Current: 17.5

During the past 13 years, the highest Price-to-Owner-Earnings of Paion Ag was 4160.00. The lowest was 0.50. And the median was 271.67.


PAIOF's Price-to-Owner-Earnings is ranked better than
69.29% of 420 companies
in the Drug Manufacturers industry
Industry Median: 28.16 vs PAIOF: 17.50

As of today (2024-05-17), Paion Ag's share price is $0.0251. Paion Ag's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.98. Therefore, Paion Ag's PE Ratio for today is At Loss.

As of today (2024-05-17), Paion Ag's share price is $0.0251. Paion Ag's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.98. Therefore, Paion Ag's PE Ratio without NRI for today is At Loss.

During the past 13 years, Paion Ag's highest PE Ratio without NRI was 81.85. The lowest was 0.00. And the median was 57.60.


Paion Ag Price-to-Owner-Earnings Historical Data

The historical data trend for Paion Ag's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Price-to-Owner-Earnings Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 360.00 - -

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Paion Ag's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion Ag's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Paion Ag's Price-to-Owner-Earnings falls into.



Paion Ag Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Paion Ag's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0251/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag  (OTCPK:PAIOF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Paion Ag Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Paion Ag's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.